Next Phase Platform – Page 12 – Dalgarno Institute

POT Shop Exemption – ‘Essential Service’? Addiction For Profit Model Exempt!

The Risk of Exempting Marijuana Businesses During COVID-19 Closures People stand in freshly painted circles, six-feet-apart, as they wait in a two-hour line to buy marijuana products from Good Chemistry on March 23, 2020 in Denver, Colorado. (Michael Ciaglo/Getty Images) An Interview with an Emergency Department Physician in Colorado I received a recent communication from […]

POT Shop Exemption – ‘Essential Service’? Addiction For Profit Model Exempt! Read More »

COVID-19, Cannabis & Cardiovascular Risk

B.M.J – Cannabis exposure as an interactive cardiovascular risk factor and accelerant of organismal ageing: a longitudinal study Apropos of the recent Covid-19 pandemic emergency it is also worth noting that since cannabis is immunosuppressive, is known to be damaging to lungs and airways and often carries chemical, microbial and fungal contaminants cannabis use and

COVID-19, Cannabis & Cardiovascular Risk Read More »

W.H.O, CBD and Challenging Misguided Recommendations

CADFY’s Statement to the Commission on Narcotic Drugs General Session – Vienna 2020 Regarding The World Health Organization’s recommendation 5.5 Recommendation 5.5: A footnote should be added to Schedule I of the 1961 Single Convention on Narcotic Drugs to read: “Preparations containing predominantly Cannabidiol (CBD) and not more than 0.2% of delta-9-THC are not under

W.H.O, CBD and Challenging Misguided Recommendations Read More »

Big Tobacco 2.O Seducing Oxford University??

Tobacco cash behind cannabis research in Oxford BMJ 2020; 368 (Published 18 March 2020) Cite this as: BMJ 2020;368:m1044 A research collaboration that includes Oxford University is taking funding from the tobacco industry for research into the medicinal properties of cannabis. Jonathan Gornall continues his investigation into the links between big business and the push to widen cannabis access for patients. The

Big Tobacco 2.O Seducing Oxford University?? Read More »

The Lancet – Single Dose of THC Could Induce Psychosis

The Lancet Psychiatry: Single dose of psychoactive component in cannabis could induce psychotic, depressive, and anxiety symptoms in healthy people THE LANCET In addition, the review found no consistent evidence that cannabidiol (CBD) moderates the effects of tetrahydrocannabinol (THC – the psychoactive component of cannabis) in healthy volunteers Single dose of THC, roughly equivalent to

The Lancet – Single Dose of THC Could Induce Psychosis Read More »

Concerns About CBD?

CONCERNS ABOUT CBD – The hype around this ‘not so new’ cannabinoid is fever pitch – but where is the actual peer-reviewed and clinically trialed evidence? The new validation of any product is now the unassailable ‘anecdote’. For your future health and well-being sake, it is vital you do your proper research and due diligence.

Concerns About CBD? Read More »